Turnstone Biologics Corp. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-03-14: Study NCT06236425; Company role Collaborator; Phase Phase 1; Status Completed.
- 2023-01-17: Study NCT05576077; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2022-11-22: Study NCT05628883; Company role Collaborator; Phase Phase 1; Status Completed.
- 2020-06-02: Study NCT04301011; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-03-14 | NCT06236425 TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | Collaborator Lead: H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Completed | Squamous Cell Carcinoma of Head and Neck; Metastatic Squamous Cell Carcinoma | 7 | 2025-04-09 |
| 2023-01-17 | NCT05576077 A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Terminated | Breast Cancer; Colorectal Cancer; Uveal Melanoma; Cutaneous Melanoma; Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma | 31 | 2025-02-24 |
| 2022-11-22 | NCT05628883 Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Collaborator Lead: H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Completed | Metastatic Melanoma; Unresectable Melanoma; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; Ocular Melanoma; Uveal Melanoma; Iris Melanoma; Conjunctival Melanoma; Non-Cutaneous Melanoma | 17 | 2025-03-06 |
| 2020-06-02 | NCT04301011 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | Lead sponsor | Phase 1 | Terminated | Solid Tumor; Microsatellite Stable Colorectal Cancer; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Cervical Cancer; Melanoma (Skin); Cutaneous Squamous Cell Carcinoma; Mesothelioma; Renal Cell Carcinoma; Oropharynx Cancer | 27 | 2023-01-23 |
| 2020-02-15 | NCT03773744 MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma | Lead sponsor | Phase 1 | Withdrawn | Metastatic Melanoma; Squamous Cell Skin Carcinoma | 0 | 2021-12-31 |
| 2018-06-21 | NCT03618953 This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers | Lead sponsor | Phase 1 | Terminated | HPV-Associated Cancers | 8 | 2021-03-05 |
| 2017-03-08 | NCT02879760 Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | Lead sponsor | Phase 1, Phase 2 | Completed | Non-Small Cell Lung Cancer | 16 | 2020-05-24 |